1525619-20-8

Basic information

• Product Name: 2-bromo-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
• CAS NO: 1525619-20-8
• Molecular Weight: 187.039
• Mol File: 1525619-20-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-bromo-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole(1525619-20-8)
• EPA Substance Registry System: 2-bromo-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole(1525619-20-8)

Safety Data

• Hazardous Substances Data: 1525619-20-8(Hazardous Substances Data)

Upstream product

• 59776-88-4 methyl-2-oxopyrrolidine-1-acetate 
• 7491-74-9 2-oxo-1-pyrrolidine acetamide 

Relevant articles and documents

Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders

Histone H3K4 methylation serves as a post-translational hallmark of actively transcribed genes and is introduced by histone methyltransferase (HMT) and its regulatory scaffolding proteins. One of these is the WD-repeat-containing protein 5 (WDR5) that has also been associated with controlling long noncoding RNAs and transcription factors including MYC. The wide influence of dysfunctional HMT complexes and the typically upregulated MYC levels in diverse tumor types suggested WDR5 as an attractive drug target. Indeed, protein-protein interface inhibitors for two protein interaction interfaces on WDR5 have been developed. While such compounds only inhibit a subset of WDR5 interactions, chemically induced proteasomal degradation of WDR5 might represent an elegant way to target all oncogenic functions. This study presents the design, synthesis, and evaluation of two diverse WDR5 degrader series based on two WIN site binding scaffolds and shows that linker nature and length strongly influence degradation efficacy.

WDR5 INHIBITORS AND MODULATORS

Described are N-(6-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)-2,3-dihydro-1H-inden-1-yl)benzamide and acetamide-containing compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and

WDR5 INHIBITORS AND MODULATORS

Described are compounds that disrupt the WDR5-MLL1 protein-protein interaction, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.